POLB 001 patent granted in South Africa

AI SummaryClose X

Poolbeg Pharma PLC has received notification of the official grant of its Immunomodulator II patent in South Africa for POLB 001, providing protection until December 2038 for the prevention of hypercytokinemia and severe influenza. This patent strengthens the company's intellectual property portfolio for POLB 001, a p38 MAP kinase inhibitor with potential applications in preventing cancer immunotherapy-induced Cytokine Release Syndrome and severe influenza, thereby enhancing its value and appeal to potential partners.

Disclaimer*

UK 100

Latest directors dealings